mt2 reta ghk-cu Dermal & Pigmentation Research Peptides Australia – Solatide Biosciences GHK-Cu 100mg Australia | Advanced
Description
Its Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint, announced September 3, 2024 (global statistical test 0.08, P = .70)
It is derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH), a naturally occurring pituitary hormone
For widespread skin conditions (psoriasis, systemic dermatitis), subcutaneous injection at 200 to 500 mcg/day may be more effective than topical alone
Eur J Cancer (2010) 46:191926
One potential disadvantage is that peptide therapy may not produce instant results
